Quick Answer
Syndax Pharmaceuticals Inc reported Total Revenue of $172.35 million for fiscal year 2025.
Syndax Pharmaceuticals Inc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $172.35M +627.8% |
$23.68M | $0.00 | $0.00 -100.0% |
$139.71M +9109.6% |
$1.52M +0.0% |
| Revenue (ASC 606) | $172.35M +627.8% |
$23.68M | $0.00 | $0.00 -100.0% |
$139.71M +9109.6% |
$1.52M +0.0% |
| Net Income | -$285.42M +10.5% |
-$318.76M -52.3% |
-$209.36M -40.2% |
-$149.34M -699.1% |
$24.93M +134.1% |
-$73.16M -30.5% |
| Diluted EPS | -$3.29 +11.6% |
-$3.72 -24.8% |
-$2.98 -21.1% |
-$2.46 -634.8% |
$0.46 +124.6% |
-$1.87 -1.6% |
| Total Assets | $529.71M -26.9% |
$724.82M +18.3% |
$612.88M +23.3% |
$497.24M +10.6% |
$449.66M +49.6% |
$300.61M +373.2% |
| Cash and Equivalents | $134.93M -12.4% |
$154.08M -47.8% |
$295.39M +297.3% |
$74.36M -66.5% |
$221.97M +92.6% |
$115.24M +368.3% |
| Stockholders Equity | $64.63M -77.6% |
$288.12M -48.0% |
$554.20M +18.6% |
$467.45M +14.5% |
$408.37M +61.9% |
$252.19M +698.1% |
| R&D Expense | $258.78M +7.1% |
$241.65M +48.2% |
$163.03M +37.6% |
$118.50M +34.3% |
$88.25M +75.0% |
$50.44M +17.3% |
| Operating Income | -$273.08M +19.6% |
-$339.67M -47.7% |
-$229.95M -51.5% |
-$151.76M -678.8% |
$26.22M +136.7% |
-$71.42M -24.1% |
| Shares Outstanding | 87.41M +2.0% |
85.69M +1.0% |
84.83M +24.5% |
68.11M +23.9% |
54.98M +14.8% |
47.88M +76.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $45.87M | +267.0% | +20.8% |
| Revenue (ASC 606) | September 30, 2025 | $45.87M | +267.0% | +20.8% |
| Net Income | September 30, 2025 | -$60.72M | +27.8% | +15.5% |
| Diluted EPS | September 30, 2025 | -$0.70 | +28.6% | +15.7% |
| Total Assets | September 30, 2025 | $551.79M | +29.6% | -7.4% |
| Cash and Equivalents | September 30, 2025 | $116.81M | -12.2% | +7.5% |
| Stockholders Equity | September 30, 2025 | $115.43M | -68.5% | -26.7% |
| R&D Expense | September 30, 2025 | $56.28M | -20.7% | -9.6% |
| Operating Income | September 30, 2025 | -$57.43M | +35.9% | +17.2% |
| Shares Outstanding | September 30, 2025 | 86.91M | +1.6% | +1.0% |
- Syndax Pharmaceuticals Inc reported Total Revenue of $172.35 million for fiscal year 2025.
- Syndax Pharmaceuticals Inc showed an increase of +627.8% in Total Revenue compared to the prior fiscal year.
- Syndax Pharmaceuticals Inc reported Revenue (ASC 606) of $172.35 million for fiscal year 2025.
- Syndax Pharmaceuticals Inc showed an increase of +627.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Syndax Pharmaceuticals Inc reported Net Income of -$285.42 million for fiscal year 2025.
- Syndax Pharmaceuticals Inc showed an increase of +10.5% in Net Income compared to the prior fiscal year.
- Syndax Pharmaceuticals Inc reported Diluted EPS of $3.29 per share (loss) for fiscal year 2025.
- Syndax Pharmaceuticals Inc showed an increase of +11.6% in Diluted EPS compared to the prior fiscal year.
- Syndax Pharmaceuticals Inc reported Total Assets of $529.71 million for fiscal year 2025.
- Syndax Pharmaceuticals Inc showed a decrease of -26.9% in Total Assets compared to the prior fiscal year.
- Syndax Pharmaceuticals Inc reported Cash and Equivalents of $134.93 million for fiscal year 2025.
- Syndax Pharmaceuticals Inc showed a decrease of -12.4% in Cash and Equivalents compared to the prior fiscal year.
- Syndax Pharmaceuticals Inc reported Stockholders Equity of $64.63 million for fiscal year 2025.
- Syndax Pharmaceuticals Inc showed a decrease of -77.6% in Stockholders Equity compared to the prior fiscal year.
- Syndax Pharmaceuticals Inc reported R&D Expense of $258.78 million for fiscal year 2025.
- Syndax Pharmaceuticals Inc showed an increase of +7.1% in R&D Expense compared to the prior fiscal year.
- Syndax Pharmaceuticals Inc reported Operating Income of -$273.08 million for fiscal year 2025.
- Syndax Pharmaceuticals Inc showed an increase of +19.6% in Operating Income compared to the prior fiscal year.
- Syndax Pharmaceuticals Inc reported Shares Outstanding of 87.41 million shares for fiscal year 2025.
- Syndax Pharmaceuticals Inc showed an increase of +2.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: